Drs Cooper and Choudhury discuss the evolving role of DLL3-targeting T-cell engagers in SCLC, with a focus on tarlatamab and how emerging trial data may reshape the current treatment paradigm across lines of therapy.
Noura Choudhury, MD
Advertisement
Articles by Noura Choudhury, MD
Noura Choudhury, MD, discusses how resistance mechanisms to tarlatamab-dlle could inform sequencing decisions in small cell lung cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILs
2
EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced Melanoma
3
Canakinumab Reduces Nodule Size in High-Risk Lung Precancers
4
Dr Graham on Data for JNJ-87189401 Plus Pasritamig in mCRPC
5